Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant results in managing excess mass and diabetes second-type disease. Initial data suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/